Long‐term mortality (time‐to‐event outcome): radiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
It is very uncertain whether non‐surgical changes long‐term mortality (time‐to‐event outcome): radiotherapy versus… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).
1 finding from 1 review
Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer
Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).
2 findings from 1 review
All‐cause mortality ( · adult patients with an implantable cardioverter defibrillator
It is very uncertain whether exercise changes all‐cause mortality ( compared with no exercise at longest available follow‐up (very low certainty).
1 finding from 1 review
All‐cause mortality
All‐cause mortality
0.14 [0, 6.98]
8 studies · 2175 participants
Moderate
Peto OR 1.06 [0.62, 1.82]
14 studies · 6173 participants
Low
All‐cause mortality
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality
It is very uncertain whether summary of findings: insulin degludec changes all‐cause mortality compared with insulin glargine (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality – deaths · adults with or without existing CVD
High showed no clear difference in all‐cause mortality – deaths compared with low long‐chain omega‐3 fats (high certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review